Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 5/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | MLNR | O43193 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | ITGAV | P06756 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6011372 | 0.85 | CHRM1 (0.44) | NMT1CHRM1CHRM3KMT2ACNR2 | |
| Hydrochloric Acid SCHEMBL6011621 | 0.84 | CHRM1 (0.43) | NMT1CHRM1CHRM3KMT2ACNR2 | |
| SCHEMBL6011463 | 0.82 | CHRM1 (0.44) | NMT1CHRM1CHRM3KMT2ACNR2 | |
| SCHEMBL8555011 | 0.82 | ALDH1A1 (0.51) | NMT1CHRM1CHRM3KMT2ACNR2 | |
| SCHEMBL6469248 | 0.81 | CHRM1 (0.45) | NMT1CHRM1CHRM3KMT2ACNR2 | |
| SCHEMBL6469254 | 0.80 | CHRM1 (0.44) | NMT1CHRM1CHRM3KMT2ACNR2 | |
| SCHEMBL6011594 | 0.80 | CRBN (0.46) | NMT1CHRM1CHRM3MLNRKMT2A | |
| SCHEMBL6011405 | 0.80 | MMP2 (0.44) | NMT1CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL5763987 | 0.78 | CRBN (0.45) | NMT1CHRM1CHRM3MLNRKMT2A | |
| SCHEMBL6011410 | 0.77 | CHRM1 (0.43) | CHRM1CHRM3KMT2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189650-A1 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1572650-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056773-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189650-A1 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | CCR5, CCR2, CCR1 | NMT1 2725/4885CHRM1 45/4885CHRM3 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.